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Abstract: The innate immune response to viral pathogens is critical in order to mobilize 
protective immunity. Cells of the innate immune system detect viral infection largely 
through germline-encoded pattern recognition receptors (PRRs) present either on the cell 
surface or within distinct intracellular compartments. These include the Toll-like receptors 
(TLRs), the retinoic acid-inducble gene I-like receptors (RLRs), the nucleotide 
oligomerization domain-like receptors (NLRs, also called NACHT, LRR and PYD domain 
proteins) and cytosolic DNA sensors. While in certain cases viral proteins are the trigger of 
these receptors, the predominant viral activators are nucleic acids. The presence of viral 
sensing PRRs in multiple cellular compartments allows innate cells to recognize and 
quickly respond to a broad range of viruses, which replicate in different cellular 
compartments. Here, we review the role of PRRs and associated signaling pathways in 
detecting viral pathogens in order to evoke production of interferons and cytokines. By 
highlighting recent progress in these areas, we hope to convey a greater understanding  
of how viruses activate PRR signaling and how this interaction shapes the anti-viral 
immune response. 
Keywords: pattern recognition receptor; toll like receptor; nod like receptor; AIM2 like 
receptor; RIG-I like receptor; cytosolic DNA sensor; inflammasome; interferon; virus 
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1. Introduction  
Cells of the innate immune system utilize pattern recognition receptors (PRRs) to identify viral 
pathogens by engaging pathogen-associated molecular patterns (PAMPs). Once thought to be moieties 
found only on pathogens our understanding of PAMPs (pathogen associated molecular patterns) has 
expanded to include not only classical PAMPS such as lipopolysaccharides found on bacteria but also 
nucleic acids. Nucleic acid sensing has emerged as a major component of the immune systems  
anti-microbial arsenal. A diverse range of pathogens are sensed via recognition of their genomes or 
nucleic acids which accumulate during their replication. Nowhere is this more prevalent than in viral 
detection. PRRs respond to signatures present in viruses such as 5‟ triphosphate RNA, which is not 
normally found in host RNA or to nucleic acids such as viral DNA which is exposed to sensors 
localized in the cytoplasm.  
Of the PRRs, the Toll-like receptors (TLRs) are perhaps the most extensively studied. TLRs are 
type 1 transmembrane proteins that traffic between the plasma membrane and endosomal vesicles.  
They are primarily responsible for detecting PAMPs in the extracellular environment. Those located 
on the plasma membrane are usually specific for hydrophobic lipids and proteins while those found in 
endosomes detect nucleic acids. This segregation appears intentional allowing innate cells to respond 
to components of the viral envelope such as fusion machinery at their surface. In contrast, nucleic 
acids are detected in the endosome where many viruses uncoat their genomes and enter the cytoplasm. 
Upon reaching the cytoplasm, viral components are subject to the scrutiny of the retinoic acid-inducble 
gene I-like receptors (RLRs), the nucleotide oligomerization domain-like receptors (NLRs) and 
cytosolic DNA sensors such as members of the AIM2 family. Similar to TLRs, RLRs and DNA 
sensors regulate transcription factors essential for the production of interferons and cytokines. In 
contrast, NLRs and AIM2 are mainly responsible for the maturation of IL-1β and IL-18 through the 
activation of caspase-1. Interestingly, the immature forms of IL-1β and IL-18 are induced by TLR 
signaling while NLRs act as a „checkpoint,‟ regulating the activation and release of these potent 
effectors. In addition to the production of proinflammatory molecules, many classes of PRRs mobilize 
the adaptive immune response by increasing expression of MHC class II and inducing expression of 
the costimulatory molecules CD40, CD80 and CD86.  
2. The Toll-like Receptors 
The Toll protein was first recognized for its role in dorsal-ventral patterning of Drosophila 
embryos. Later studies found it to be important for the adult fly‟s immune response to bacterial and 
fungal infections fueling the search for mammalian homologs. To date, 10 TLRs have been identified 
in humans, 13 in mice with TLRs 1-9 common to both. TLR1, TLR2, TLR4, TLR5 and TLR6 are 
located on the plasma membrane while TLR3, TLR7, TLR8, and TLR9 are endosomal. All TLRs share 
a common architecture consisting of extracellular leucine-rich repeats and a cytoplasmic 
Toll/Interleukin-1 Receptor (TIR) domain [1]. These receptors signal as dimers, differentially 
recruiting the adaptor proteins Mal (MyD88 adapter-like), also called TIRAP (TIR domain-containing 
adaptor protein) and MyD88 (Myeloid differentiation primary response gene 88) and/or TRIF 
(TIR-domain-containing adaptor inducing IFNβ) and TRAM (Trif-related adaptor molecule) [1]. 
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Adaptors initiate signal cascades culminating in the activation of nuclear factor kappa b (NF-κB), 
mitogen-activated protein kinase (MAPK) and interferon regulatory factors 1, 3, 5 and 7 (IRF-3, -5  
and -7) [2]. Together these transcription factors not only drive expression of interferons, cytokines and 
chemokines but also influence cellular maturation and survival.  
2.1. TLR Signaling 
With the exception of TLR3 all TLRs recruit MyD88 upon activation. In the case of TLR2 and 
TLR4, the Mal/TIRAP protein acts as a bridging adapter to recruit MyD88 to the activated receptor 
[3]. MyD88‟s death domain associates with and activates IL-1R-associated kinase 1 (IRAK-1) and/or 
IRAK-2. IRAK-4 also transiently interacts with this complex and is thought to phosphorylate IRAK-1. 
IRAK-1 is subsequently released and engages TNFα receptor-associated factor 6 (TRAF6). Activated 
TRAF6 is capable of K63-linked polyubiquitination of itself and other proteins. It interacts with 
NF-κB essential modulator (NEMO, also known as IKKγ), another of its ubiquitination targets, as well 
as TGF-β-activated kinase-1 (TAK1) and the TAK1 binding proteins (TAB1, TAB2 and TAB3). 
NEMO forms a complex with IKKα and IKKβ, which are the catalytic kinases responsible for 
phosphorylating IκB. IκB binds to and sequesters NF-κB in the cytoplasm. Following phosphorylation, 
IκB is ubiquitinated and finally degraded by the proteasome releasing NF-κB to enter the nucleus and 
induce gene expression. Studies indicate that TAK1 plays an essential role in both the NF-κB and 
MAPK pathways by phosphorylating IKKβ and c-Jun N-terminal kinase (JNK), respectively [4,5]. 
TLR3 is incapable of recruiting MyD88 and instead interacts with the adaptor protein TIR-domain-
containing adapter-inducing interferon-β (TRIF). TRIF can directly bind TRAF6 and induce NF-κB in 
a manner similar to MyD88. In contrast to MyD88, TRIF is also able to recruit the protein receptor 
interacting protein-1 (RIP-1). RIP-1 synergizes with TRAF6 resulting in more potent NF-κB 
activation. A third protein recruited to TRIF is TRAF3. TRAF3 associates with TANK binding  
kinase-1 (TBK1) and IKKi and is essential for the production of type I interferon. TBK1 and IKKi 
mediate this production by phosphorylating interferon regulatory factor-3 (IRF3) and IRF7.  
This allows them to dimerize and enter the nucleus where they cooperate with NF-κB and activator 
protein 1 (AP-1) to bring about target gene transcription. TLR4 can recruit TRIF through the adaptor  
TRIF-related adaptor molecule (TRAM) and can therefore signal through either pathway.  
A number of primary immunodeficiencies in humans are the result of defects in the innate signal 
pathways described above. For instance, one study of children with nonfunctional MyD88 proteins 
found they were predisposed to recurrent life-threatening pyogenic bacterial infections [6]. A similar 
phenotype has been reported in patients with IRAK-4 deficiency [7]. A study of two unrelated children 
with defects in UNC-93B1, a protein thought to be involved in trafficking TLR3, TLR7, TLR8 and 
TLR9 to the endosome, found an increased susceptibility to encephalitic herpes simplex virus-1 
infection [8]. PBMCs and fibroblasts derived from these children demonstrated a reduced type I 
interferon response to HSV-1 challenge and a concomitant enhancement in viral replication [8]. 
2.2. TLR Expression and Activity 
The inflammatory response evoked by viral PAMPs depends on a variety of factors. Firstly, cellular 
expression of TLRs differs between innate cell types. Human macrophages are known to express high 
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levels of TLR2 and TLR4 while plasmacytoid dendritic cells (pDCs) mainly express TLR7 and 
TLR9 [1]. Expression patterns also vary between species, where TLR9 is restricted to a few cell types 
in humans it is widely distributed in mice. Furthermore, expression of certain downstream signaling 
molecules fluctuates between innate cell types. For example, pDCs are unique in that they 
constitutively express the transcription factor IRF7 allowing them to quickly produce high levels of 
type I IFNs in response to viral infection while other cell types such as macrophages may respond in a 
more delayed manner [2,3]. Thus, the response to identical viral PAMPs may differ between cell types 
both in the nature of effector molecules produced and the kinetics of the response. Virally encoded 
proteins that subvert or distort the TLR response often further complicate this picture. In the 
subsequent sections we discuss the TLRs individually, detailing the viruses they detect and wherever 
possible the specific viral products sensed. 
2.3. TLR4 
The TLR4-mediated response to LPS is well known for its critical role in innate immune control of 
Gram-negative bacterial infection. It was also the first TLR shown to respond to a viral pathogen. In 
2000, Kurt-Jones et al. reported the interaction between the fusion (F) protein of respiratory syncytial 
virus (RSV) and TLR4 [4]. The importance of TLR4 in human viral disease and RSV pathogenesis has 
been documented in genetic studies. In humans, inheritances of two different single nucleotide 
polymorphisms (SNPs) in the ectodomain of TLR4 are associated with reduced responses to both LPS 
and RSV F. A highly significant association was found between RSV infection in high-risk infants and 
inheritance of hyporesponsive TLR4 SNPs [5]. This was confirmed in a separate study that likewise 
found a significant association between these same TLR4 SNPs and severity of RSV disease in 
infants [6].  
Initial studies linking TLR4 expression to RSV pathogenesis were done in the TLR4-deficient 
mouse strain C57BL10ScNCr (which has a deletion of the gene region containing TLR4) as well as in 
C3H/HeJ mice (non-signaling point mutation of TLR4) [4,7]. These studies found that RSV activated 
NF-B in a TLR4-dependent manner at early time points of infection [8]. The original RSV infection 
studies with ScNCr mice were controversial as it was suggested that the failure to control RSV was 
due to a defect in IL-12R signaling [9]. However, this discrepancy between the different studies was 
due in part to confusion about the mouse nomenclature since the ScNCr mice used in the initial studies 
(but misidentified as ScCR in the paper [4]) have normal IL-12R [10] while the ScCr mice used by the 
second group were IL-12R-deficient [9]. More recent work using targeted TLR4 knockouts on a B6 
background (with normal IL-12R) have confirmed the role of TLR4 in controlling RSV replication 
independent of IL-12R, but interestingly these studies have also revealed an even more important role 
for TLR2 in limiting RSV replication [11]. The purified F protein of RSV induced IL-6 production in a 
dose-dependent manner in human peripheral blood mononuclear cells (PBMCs) and wild type mouse 
macrophages alike. However, this response was lost in TLR4 deficient and TLR4 knockout 
macrophages [4,11]. Studies by Vogel and colleagues have shown that the ability of TLR4 to be 
triggered by RSV F is critical to prevent RSV-induced pathology. Indeed, the formalin-inactivated 
RSV vaccine which caused exacerbated disease in clinical trials and was found to contain a denatured, 
non-stimulatory F protein. The disease enhancing activity of the formalin-inactivated RSV vaccine 
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could be reversed by the addition of MPL, a non-toxic lipid A TLR4 agonist [12]. Disease severity is 
also correlated with the absence of “alternatively activated” (AA) macrophages that play a crucial role 
in tissue repair [13]. Taken together with the human and mouse genetics, these studies suggest that 
TLR4-F protein interactions may protect the host from severe RSV disease by mitigating or 
reprogramming the host response to promote AA-macrophages and thus promote healing [14].  
TLR4 is also important for infections by the retrovirus mouse mammary tumor virus (MMTV). 
MMTV was shown to activate NF-B and induce B220 and CD69 lymphocyte activation markers in B 
cells from wild type but not C3H/HeJ or congenic BALB/c (C.C3H Tlr4
lps-d
) lines [15]. TLR4 
activation, attributed to the envelope (Env) protein, was found to stimulate production of IL-10 [16]. 
Surprisingly induction of TLR4 signaling appears to benefit MMTV. First, it activates quiescent B 
cells encouraging cell division, which is necessary for viral genome integration in the host 
chromosome. Secondly, it promotes secretion of IL-10, an immunosuppressive cytokine that helps the 
virus persist indefinitely [15].  
2.4. TLR2 
Functional TLR2 exists as a heterodimer with either TLR1 or TLR6 on the plasma membrane of 
both innate and adaptive immune cells. It can be activated by lipoteichoic acid, a common component 
of gram-positive bacteria, as well as GPI anchors of parasitic protozoan such as Plasmodium 
falciparum. The TLR2/TLR6 heterodimer has recently been shown to play a role in the innate immune 
response to RSV. Macrophages from mice deficient in TLR2 or TLR6 responded to RSV with lower 
levels of TNF, IL-6, CCL2 (MCP-1) and CCL5 (RANTES) than their wild type counterparts. When 
TLR2 or TLR6 knockout mice were challenged intranasally with RSV they had elevated peak viral 
titers and lower numbers of neutrophils and activated DC in their lungs [11]. Thus, TLR2/TLR6 
signaling likely contributes to both innate immune cell recruitment and viral clearance in vivo during 
RSV infection [11]. In human PBMCs, TLR2 contributes to IL-8 and MCP-1 production in response to 
Epstein-Barr virus (EBV) [17]. A TLR2/TLR1-mediated proinflammatory response to the related 
human cytomegalovirus (HCMV) has also been reported. One study found TLR2 deficient mouse 
macrophages had significantly reduced IL-6 and IL-8 production in response to UV-inactivated 
HCMV [18]. Furthermore, expression of TLR2 and CD14 was required for maximal NF-B activation 
and IL-8 secretion in HEK293 cells exposed to HCMV. Envelope glycoproteins B and H were later 
shown to coimmunoprecipitate with TLR2 and TLR1 and are theorized to be the HCMV PAMPs 
stimulating TLR2 [19].  
Lymphocytic Choriomeningitis (LCMV) is a non-cytolytic virus that can cause fatal encephalitis in 
mice. Wild type glial cells infected with LCMV produce TNF, CCL2 and CCL5, a response that is 
abolished in cells derived from TLR2 deficient mice [20]. TLR2 also induces MHC class-I and  
class-II, CD40 and CD86 expression in microglia challenged with LCMV, implicating this pathway in 
the induction of adaptive immunity [20]. In LCMV infection, where much of the CNS damage is 
caused by the immune response itself, it remains to be determined if TLR2 signaling is protective or 
pathological. Interestingly, TLR2 is important for type I IFN induction during LCMV infection but the 
mechanism is unclear [21]. Although TLR2 is normally not associated with type I IFN induction, a 
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recent study from Barton and colleagues demonstrated that on inflammatory monocytes, TLR2 
regulates induction of type I interferon in response to viral but not bacterial ligands [22].  
Surprisingly, it appears TLR2 can play either a protective or detrimental role in disease caused by 
herpes simplex virus (HSV) depending on the context of the infection. Studies using an intraperitoneal 
infection model found TLR2 deficient neonates were protected from lethal HSV-1 encephalitis 
compared to wild type mice [23]. Despite having similar viral loads, the TLR2 knockouts 
demonstrated improved survival, attenuated symptoms and reduced CNS inflammatory lesions. In 
contrast, TLR2 was shown to work synergistically with TLR9 to promote survival in an intranasal 
HSV-1 infection model [24]. In addition, TLR2 has been shown to be beneficial in both intraperitoneal 
and intravaginal HSV-2 infection models [25]. TLR2‟s role in murine HSV infection models may be 
influenced by factors such as the size of the viral inoculum, the route of administration and the age of 
the subject. HSV induced two distinct responses; a TLR2-dependent inflammatory cytokine response 
and a TLR9 and/or non-TLR-dependent type I IFN response. A strong IFN response is necessary to 
control early virus replication (IFN-deficient mice quickly succumb to infection) and prevent spread 
from the genital tract to the brain [25]. Once in the brain, however, inflammation is linked to increased 
mortality [23].  
Measles virus (MV) is another infection in which TLR2 signaling may have both favorable and 
unfavorable effects. Challenging mice with live or UV-inactivated wild type MV induces IL-6 
production and CD150 surface expression in mouse macrophages; a response that is impaired in 
TLR2-deficient cells [26]. Intriguingly, CD150 is required for entry of wild type MV into monocytes, 
thus immune activation through TLR2 may in fact benefit the virus by conferring susceptibility. This 
study identified MV hemaglutinin (HA) protein as the viral PAMP triggering TLR2 activation [26]. 
MV vaccine strains carrying a single asparagine to tyrosine substitution in the HA protein lacked the 
ability to activate TLR2.  
2.5. TLR3 
With the exception of neutrophils and pDCs, TLR3 is widely expressed in innate immune cells 
where it is localized to the endosomal compartment [27,28]. In 2001, Alexopoulou et al. demonstrated 
that activation of TLR3 signaling by the double stranded RNA analog poly(I:C) contributed to the 
production of type I IFN and cytokines in macrophages. Moreover, genomic dsRNA isolated from 
reovirus was found to activate wild type but not TLR3 deficient splenocytes. The idea that TLR3 could 
respond to dsRNA, a common viral PAMP, led to intense speculation about its role in the host 
response to numerous infections. Counterintuitively, a later study found no difference in the survival, 
viral titers or pathology of TLR3 deficient mice following reovirus challenge [29]. The authors 
suggested that during in vivo infection, TLR3 may not encounter reovirus dsRNA or that levels may be 
too low to efficiently activate TLR3 [29]. This study also reported indistinguishable immune responses 
to LCMV, VSV and MCMV infection in TLR3 deficient and wild type mice [29]. However, other 
evidence exists suggesting that TLR3 does in fact play a role in controlling MCMV as some studies 
observed blunted type I IFN and IL-12 production accompanied by higher viral loads in the spleens of 
mice lacking TLR3 [30,31]. Despite this, only TLR9 deficient mice had significantly decreased 
survival compared to wild type suggesting TLR9 is more crucial than TLR3 in MCMV infections [30]. 
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A recent study also implicates TLR3 in immune suppression of the related herpes virus HSV-1. 
Patients with TLR3 dominant negative mutations were found to be more susceptible to herpes simplex 
encephalitis, a rare but devastating manifestation of HSV-1 infection [32]. The presumed ligand for 
TLR3 in infections with DNA viruses is dsRNA generated during bidirectional transcription of 
opposing DNA strands. TLR3 signaling also reduces lethality of encephalomyocarditis virus (EMCV), 
a ssRNA virus that directly damages heart tissue [33]. TLR3 deficient mice challenged with EMCV 
had decreased levels of TNF, IL-6 and IL-1 mRNA in cardiac tissue and a corresponding reduction 
in inflammatory infiltrate at 3 days post infection [33]. Without TLR3 signaling, EMCV replicated to 
higher levels in the heart resulting in more rapid and extensive mortality in knockouts [33].  
Although this study indicates that the TLR3-mediated inflammatory response is beneficial in 
EMCV infections; TLR3 signaling appears to be detrimental in a number of other viral infections. For 
instance, TLR3 deficient mice were protected compared to their wild type counterparts when 
challenged with a lethal dose of West Nile Virus (WNV) [34]. This study found that TLR3 driven 
production of inflammatory cytokines compromised the blood-brain barrier facilitating WNV entry. 
This resulted in higher viral loads in the CNS and worsened neuropathology. Likewise, TLR3 was 
shown to play a pathologic role in infections with Punta Toro Virus (PTV) [35]. Wild type mice had 
drastically reduced survival and increased hepatic injury compared to TLR3 deficient mice following 
PTV challenge. Despite having similar serum and hepatic viral loads, wild type mice had elevated 
levels of IL-6, IFN, CCL2 and CCL5, suggesting these proinflammatory molecules may mediate 
much of the damage observed [35]. Interestingly, although TLR3 signaling increases inflammation and 
reduces Influenza A virus (IAV) lung titers, it causes a paradoxical decrease in survival. Thus, in IAV 
infections, lethality appears to be more dependent on TLR3 signaling than direct virus-induced injury.  
2.6. TLR7 and TLR8 
TLR7 and TLR8 are two closely related receptors that, like TLR3, act in the endosome. Human 
TLR7 and TLR8 were first shown to respond to the imidazoquinoline-like compound resiquimod  
(R-848), a synthetic drug recognized for its antiviral and antitumor activity [36,37]. We now know that 
nearly any long single-stranded RNA (ssRNA) is capable of activating TLR7 and TLR8 [38]. Despite 
this, differences do exist between these receptors. For example, short dsRNAs containing certain 
motifs preferentially activate TLR7 [39,40]. Furthermore, synthetic agonists specific to TLR7 or TLR8 
differentially activate innate immune cells leading to distinct cytokine profiles [41]. In 2004,  
Diebold et al. showed that TLR7 mediates IFN production by pDCs in response to live or  
heat-inactivated influenza virus [42]. This TLR7 response could be elicited simply by exposure to 
purified genomic ssRNA and was completely abrogated by chloroquine, an inhibitor of endolysosomal 
acidification [42]. Thus, the authors proposed a model, now known as the exogenous pathway, 
whereby pDCs endocytose and degrade a portion of incoming influenza virions, allowing TLR7 to 
engage exposed genomic RNA. A similar TLR7-dependent type I interferon response was observed 
when pDCs were challenged with vesicular stomatitis virus (VSV) [43]. Under normal circumstances 
both influenza and VSV require endocytosis for viral entry. However, using a recombinant strain of 
VSV (VSV-RSV-F), capable of fusing to the plasma membrane, Lund et al. demonstrated that VSV 
activated TLR7 regardless of the route of viral entry. TLR7 is also responsible for pDC production of 
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IFN in response to Sendai virus (SV); another ssRNA virus which enters at the plasma 
membrane [44]. Interestingly studies of SV using human U937 and murine RAW 264.7 myeloid lines 
found only a partial role for TLR signaling in cytokine and chemokine production [45]. Recent 
evidence suggests the cytosolic RLR receptors are chiefly responsible for the cytokine and interferon 
response to SV in myeloid cell types other than pDCs [46]. 
One important observation gleaned from studies using SV and VSV was that, in contrast to 
influenza, UV-inactivation of these virions abolished TLR7 activation [44]. From this work a second 
model of TLR7 activation known as the endogenous pathway was proposed. According to this theory, 
ssRNA intermediates produced during SV and VSV infection are transferred from the cytoplasm to the 
endosome by means of autophagy [44]. Thus, to elicit a TLR7 response by this route, cells must be 
exposed to live, replication competent virus. This model is supported by studies showing that selective 
inhibitors of autophagy and mice deficient in autophagic pathways lack a TLR7 mediated response to 
SV and VSV [44]. Recent studies have implicated TLR7 and TLR8 in the response to human 
immunodeficiency virus (HIV). ssRNA derived from the HIV genome caused murine pDCs and 
macrophages and human PBMCs to produce IFN, IL-6 and TNF [47]. In mice this activity was 
TLR7-dependent while in humans it appears to rely on TLR8 suggesting that HIV receptors may be 
species-specific. A study by Wang et al. found IFN production by human and mouse pDCs 
responding to Coxsackievirus B (CVB) was also dependent on TLR7 [48]. Interestingly, this response 
required the presence of CVB-specific antibodies as well as functional Fc Receptor complexes on the 
pDC surface. Thus they proposed a mechanism whereby opsonized CBV is delivered to the endosome 
via FcR and once internalized viral RNA is detected by TLR7 [48]. This observation suggests previous 
exposure to CVB can influence subsequent innate responses furthering our understanding of the 
complex interplay between adaptive and innate immunity.  
2.7. TLR9  
In both humans and mice, TLR9 is highly expressed in pDCs, innate cells renowned for their ability 
to rapidly produce large amounts of type I interferon [1]. TLR9 responds to the unmethylated 
deoxycytidylate-phosphate-deoxyguanylate (CpG) motifs in viral and bacterial DNA [49]. Not 
surprisingly TLR9 has been shown to play a crucial role in infections caused by a number of DNA 
viruses. For instance, TLR9 deficient mice infected with MCMV have a drastically increased mortality 
compared to their wild type counterparts. This hypersensitivity is likely due to the blunted type I IFN 
and IL-12 response and reduced NK cell activation which results in an elevated MCMV load [30]. In 
EBV infection, production of type I IFN, IL-6 and IL-8 by pDCs is largely dependent on TLR9 [17]. 
This is in contrast to monocytes where TLR2 synergizes with TLR9 to orchestrate the cytokine 
response to EBV [17]. TLR9 signaling also plays a role in the interferon response to HSV types I and 
II. One study found IFN production by mouse pDCs in response to HSV-2 was completely dependent 
on TLR9 and independent of viral replication [50]. Using cholorquine it was shown that this 
recognition required endosomal maturation and could be evoked simply by exposure to purified  
HSV-2 DNA [50]. Furthermore, following in vivo HSV-2 challenge, IFN was only detectable in the 
serum of mice with intact TLR9. A similar role for TLR9 was described in the response to HSV-1 by 
splenic pDCs. However, this study also described a delayed IFN response by conventional dendritic 
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cells (cDCs) and macrophages that was both TLR9 and MyD88-independent but required exposure to 
replication competent virus. The TLR9-independent IFN response is likely due to cytoplasmic RLRs 
and may explain why one study using TLR9 deficient mice identified no in vivo defects in the HSV-1 
control [51]. Alternatively, TLR9 signaling may be more important in certain manifestations of HSV-1 
induced disease. A recent study showed TLR9 deficient mice did have higher rates of mortality and 
viral replication when challenged intranasally with HSV-1 [24]. Thus TLR9‟s precise role in HSV 
pathogenesis and the relative contributions of other PRRs requires further investigation. Figure 1 
illustrates the TLRs activated by viral pathogens and depicts their downstream signal pathways. 
Figure 1. Cell surface and endosomal recognition of viruses by Toll-like receptors (TLRs). 
TLR2 responds to a variety of viruses resulting in activation of a MyD88-dependent  
NF-κB and MAPK pathway. TLR4, responding to viral proteins (e.g., RSV F-protein) 
activates both a MyD88-dependent and MyD88-independent response. The MyD88-
dependent response leads to transcriptional regulation of inflammatory cytokines, while the 
MyD88-independent response is regulated via TRAM/TRIF and the IKK-related kinases 
which drive IRF3 activation and type I Interferon production. In the endosome, TLR3, 
TLR7, TLR8 and TLR9 sense viral nucleic acids and generate either IRF3 activation 
(TLR3) or IRF7-driven type I IFNs (TLR7, 8 and 9).  
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3. Intracellular Nucleic Acid Sensors 
As discussed above, the TLRs play an important role in sensing viral PAMPS that are present 
within the extracellular compartment, as well as in endosomes. In certain contexts, TLRs can receive 
viral nucleic acids generated from viruses that replicate in the cytoplasm, via an autophagy 
mechanism. A role for intracellular sensors in the clearance of viruses that replicate and reside within 
the cytosol of cells has recently emerged. Following the generation of mice lacking TLRs and 
examination of their susceptibility to virus infections, it became clear that additional sensing 
mechanisms must also exist and contribute to anti-viral defenses. The last decade or more has revealed 
numerous additional classes of innate sensors. Of particular relevance to anti-viral defenses was the 
discovery of specialized classes of cytosolic nucleic acid sensors, termed RIG-I like receptors (RLRs), 
which recognize intracellular RNA that is introduced to the cytosol during viral infection or that 
accumulates during replication. Additionally, a diverse selection of intracellular DNA sensors which 
recognize viral DNA within the cytosol have also emerged.  
3.1. The RIG-I like Receptor Family 
The RLR family is comprised of three DExD/H box RNA helicases: retinoic acid-inducible gene 
(RIG-I), melanoma differentiation-associated gene 5 (MDA-5), and laboratory of genetics and 
physiology-2 (LGP-2) [60–64]. Both RIG-I and MDA-5 are comprised of tandem N-terminal caspase 
activation and recruitment domains (CARDs) followed by a DExD/H box RNA helicase domain which 
has ATPase activity and a C-terminal repressor domain (RD). Unlike RIG-I and MDA-5, LGP-2 lacks 
the N-terminal CARD domains, containing only the RNA helicase domain. As such, LGP-2 was 
postulated to act as a negative regulator of the other RLRs [61,63]. Under resting conditions, RIG-I 
resides in the cytoplasm in an inactive form that is auto inhibited by its regulatory domain. Upon viral 
infection, RIG-I undergoes a conformational change by which it dimerizes in an ATP dependent 
manner [63]. The activated multimeric form of RIG-I or MDA5 then interacts with the downstream 
adaptor protein mitochondrial antiviral signaling protein (MAVS), also known as VISA, IPS-1, and 
CARDIF, via CARD-CARD interactions. MAVS is localized to the outer leaflet of the mitochondrial 
membrane, which is an essential location to support downstream signaling. Recently, MAVS was also 
shown to be localized on peroxisomes, from where it induces an early antiviral response through the 
direct induction of a subset of anti-viral genes via the transcription factor IRF1. Upon engagement of 
RIG-I or MDA5 with MAVS, MAVS activates the IKK-related kinase, TBK1/IKKi, which activates 
IRF3/IRF7, resulting in the transcription of type I interferons. MAVS also activates NF-κB through 
recruitment of TRADD, FADD, caspase-8, and caspase-10 [65–69]. 
3.2. RNA Recognition by RLRs 
The RLRs are critical components of the anti-viral defense pathway in many cell types including 
fibroblasts, epithelial cells, and conventional dendritic cells [70]. Initially, it was thought that both 
RIG-I and MDA-5 recognized the synthetic dsRNA, polyinosinic acid (polyI:C). However, studies 
from RIG-I and MDA-5 deficient mice determined that MDA-5 alone was responsible for interferon 
production by polyI:C stimulation [71]. Instead, RIG-I recognizes 5‟-triphosphorylated, uncapped 
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ssRNA, which is a common feature in many viral genomes. However, it is unable to recognize the 
capped 5‟-ppp ssRNA from the host cell [72–74]. These finding suggest that RIG-I uses the 5‟ end of a 
transcript to discriminate between viral and host RNA. MDA-5 distinguishes between viral and host 
RNA not by its 5‟ end, but rather by the length of the RNA sequence; long dsRNA is not naturally 
present in host cells and acts as a ligand of MDA-5. In addition to recognizing 5‟-triphosphate RNA, 
RIG-I is also capable of recognizing short dsRNA, which is produced as a byproduct of viral 
replication [75].  
RIG-I and MDA-5 appear to differentially recognize different classes of RNA viruses. Studies 
involving RIG-I deficient mice implicated RIG-I in the recognition of vesicular stomatitis virus (VSV), 
rabies virus, SV, Newcastle disease virus (NDV), RSV, measles virus, Influenza A and B, hepatitis C 
virus (HCV), Japanese encephalitis virus, and ebola virus [53,70,71,76–78]. Studies from MDA-5 
deficient mice show that MDA-5 is able to recognize EMCV, theiler‟s virus, and mengo virus [71,77]. 
All of these viruses do not contain a 5‟ triphosphate RNA, but are able to produce long dsRNA, 
providing further evidence that MDA5 discriminates between self and non-self RNA based on 
sequence length and not the 5‟triphosphate. More recently studies have shown that both CVB and 
poliovirus are dependent on MDA-5 for type I IFN production [79,80]. Moreover, some viruses,  
such as dengue, West Nile virus, and reovirus, signal through a combination of both RIG-I and  
MDA-5 [79,81,82].  
As discussed above, LGP-2 lacks N-terminal CARD domains, and was first thought to be a negative 
regulator of RLR function [61,63]. Initial studies found that overexpression of LGP-2 decreased the 
capacity of SV and NDV to induce interferon production. Evidence that LGP-2 could associate with 
RIG-I through mutual RD domains led to the proposal that LGP-2 directly prevented RIG-I association 
and activation. Consistent with this idea, interferon signaling was found to be increased in LGP-2 
deficient mice responding to polyI:C, providing evidence for negative regulation of MDA-5 as well [83]. 
A second in vivo study using LGP-2 deficient mice as well as mice harboring an inactive ATPase in 
the DExD/H-box RNA helicase domain showed that LGP-2 acted as a positive regulator of RIG-I and 
MDA-5-mediated signaling after infection by RIG-I and MDA-5-specific RNA viruses. This 
phenotype is consistent with the possibility that LGP-2 might promote RNA accessibility, thus 
enabling RIG-I or MDA-5 dependent viral recognition. Further studies on these mice will no doubt 
clarify this upstream mechanism and the role of LGP-2 in this pathway.  
3.3. DDX3 
Another member of the DExD/H box RNA helicase family, DDX3, has also recently been 
implicated in anti-viral defenses. Schroder et al. found that the vaccinia virus protein K7 inhibited 
IFNβ induction by binding to DDX3, which led to the discovery that DDX3 had a positive role in the 
RLR signaling pathway [84]. A more recent study reported that DDX3 binds to both polyI:C and viral 
RNA introduced into the cytosol and associates with MAVS/IPS-1 to upregulate IFNβ production. 
These results led the authors to speculate that DDX3 might enhance RNA recognition, forming a 
complex with RIG-I and MAVS to induce interferon production [85]. Further studies are required to 
determine whether DDX3 is a bona fide RNA sensor or a component of the RLR signaling pathway in 
order to fully understand the function DDX3 plays in anti-viral surveillance and signaling.  
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3.4. Cytosolic DNA Sensors 
Prior to the discovery of TLR9, it was known that DNA derived from pathogens could activate 
fibroblasts to produce type I IFNs [86]. This phenomenon was ignored or underestimated for decades 
and was rediscovered following the observation that transfection of pathogen-derived dsDNA activated 
a TLR9 negative thyroid cell line to upregulate various immunological genes [87]. Akira and 
colleagues subsequently demonstrated that TLR9−/− MEFs, which failed to respond to CpG DNA, 
produced large amounts of IFN in response to transfection with synthetic b-form dsDNA or genomic 
DNA isolated from bacteria, viruses, and mammalian cells [87]. This was similar to findings presented 
by the Medzhitov lab using a 45 bp dsDNA region from the Listeria monocytogenes genome. 
Cytosolic administration of dsDNA did not appear to utilize any known TLRs to induce interferon 
since cells from mice lacking both MyD88 and TRIF responded normally.  
Like the cytosolic RNA recognition pathways, cytosolic DNA recognition also leads ultimately to 
activation of TBK1 and IRF-3 and production of type I IFNs. However, the signaling pathway linking 
upstream DNA sensors to TBK1 are poorly characterized. TBK1 associates with DDX3, a DEAD box 
RNA helicase, which regulates IFNβ transcription via IRF-3 [84,85]. In addition, TBK1 interacts with 
the exocyst protein Sec5 in a complex that includes the recently identified endoplasmic reticulum (ER) 
adaptor stimulator of interferon genes (STING) [69,88–90]. STING plays a central role in the signaling 
pathway upstream of TBK1 following HSV infection [69]. STING also interacts with the ER 
translocon components Sec61β and TrapB in a manner essential for regulation of cytosolic  
DNA-induced type I IFN production, although the mechanistic understanding of this finding is not 
known [88]. In unstimulated cells, STING localizes to the ER and perhaps ER-associated mitochondria 
[90]. Following stimulation with cytosolic DNA and HSV-1, STING translocates to perinuclear foci, 
via the Golgi [88]. STING localizes partially to endosomes, particularly Sec5 positive structures [88], 
whilst another report has demonstrated that STING localizes to vesicular structures, which are not 
peroxisomes, mitochondria, endosomes or autophagosomes [91]. Further work is required to clarify the 
precise subcellular localization of STING. What is clear is the essential role of STING in cytosolic 
DNA sensing pathways. Much less clear is the mechanisms or receptors which act upstream of STING. 
A growing number of DNA sensors have now been implicated and will be outlined below. 
3.5. DAI 
DNA-dependent activator of IFN-regulatory factors (DAI) was among the first of the cytosolic 
DNA sensors to be discovered. It is composed of two binding domains for left-handed, Z form DNA, 
although the protein can recognize B form DNA as well. When DAI was exogenously expressed in 
L929 cells, it increased type I IFN production in a dose dependent manner following stimulation by 
both B and Z form DNA. Similarly, knockdown of DAI with siRNA impaired type I IFN production in 
response to DNA, the 45 bp interferon stimulatory DNA (ISD) from Listeria and the herpesvirus, 
HSV-1 [92,93]. The production of type-1 interferons by fibroblasts in response to HCMV was also 
found to be dependent on DAI [94]. DAI-knockout mice were subsequently generated, and 
surprisingly, cells derived from DAI deficient mice respond normally to synthetic and viral dsDNA 
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[92,95]. These results suggested that DAI might play a cell type specific, and redundant role in sensing 
cytoplasmic DNA, and that other sensors must also be necessary for inducing these responses.  
3.6. RNA Pol III 
As discussed above, both synthetic and viral RNA trigger the production of type I IFNs via RIG-I. 
Although, the RLRs are sensors of RNA, some data has suggested a role for this system in detection of 
DNA. A somewhat surprising finding was that synthetic B-form dsDNA can also induce IFN 
production in human cells in a manner that was dependent on the RIG-I adapter molecule MAVS  
[52–54]. These findings suggested the existence of an unknown DNA sensor that would signal via 
MAVS. Recently, two independent studies have provided an explanation for these findings and shown 
that AT-rich DNA can be transcribed by RNA polymerase III into 5'-ppp RNA, which subsequently 
activates RIG-I [52,55]. This pathway was reported to be involved in type I IFN induction during EBV 
infections where the EBERs are transcribed by RNA polymerase III [56]. This indirect DNA-sensing 
system was also reported to be involved in induction of type I IFN following HSV-1 or Legionella 
infection [52,55,57]. 
3.7. LRRFIP1 
In addition to DAI and RNA Pol III, Leucine-rich repeat flightless-interacting protein 1 (LRRFIP1) 
has recently been implicated as a regulator of DNA-driven innate immune signaling. LRRFIP1 was 
found to bind to the drosophila homolog flightless I and play a role in actin organization during 
drosophila embrogenesis. In a study using Listeria monocytogenes to screen for potential cytosolic 
DNA sensing molecules, siRNA against LRRFIP1 was found to inhibit type I IFN production induced 
by the bacteria. The authors showed that the IFN response to VSV was dampened in these cells as 
well. Furthermore, knockdown of LRRFIP1 inhibited IFN production in response to polyI:C, and the 
synthetic DNA species, poly(dG:dC) and poly(dA:dT), implicating LRRFIP1 in the recognition of 
both dsRNA and both B and Z form dsDNA. Surprisingly, this function is independent of RNA Pol III. 
LRRFIP1 does not regulate IRF3 activation but instead appears to regulate a novel β-catenin-
dependent coactivator pathway. LRRFIP1 binds RNA or DNA and leads to phosphorylation of 
β-Catenin, which subsequently translocates to the nucleus where it associates with the p300 
acetyltransferase at the IFNβ1 promoter, leading to increased IFNβ production [101]. Although 
LRRFIP1 has been implicated in the recognition of both Listeria monocytogenes and VSV, further 
studies are needed in order to determine its role in sensing other viruses, particularly DNA viruses.  
3.8. IFI16 
While analyzing immune responses to a dsDNA region derived from the VV and HSV-1 genomes, 
Bowie et al. identified IFI16 as a DNA binding protein which interacted with these dsDNAs. IFI16 is a 
member of the PyHIN (pyrin and HIN200 domain-containing) protein family. The PHYIN family 
consists of 4 family members: IFIX, IFI16, MNDA and AIM2. All contain one or more HIN200 
domains, which recognize DNA as well as a pyrin domain. Knockdown of IFI16 or p204 (a member of 
the murine PYHIN family) led to a reduction in IFNβ responses to these dsDNAs while responses to 
Viruses 2011, 3              
 
 
933 
the RNA virus SV was unaffected. Although IFI16 is primarily nuclear in most cell types, in 
macrophages IFI16 also localized to the cytosolic compartment where it co-localized with dsDNA 
introduced via lipofectamine. Association of IFI16 with STING was required for the production of 
IFNβ in response to these DNA motifs. siRNA knockdown of IFI16, and its mouse homolog p204 led 
to a decrease in IRF3 and NF-κB activation and IFNβ gene induction following infection of cells with 
HSV-1 [102].  
3.9. DDX9 and 36 
Also in the family of DExD/H box RNA helicases, DHX9 and DHX36 have recently been shown to 
recognize and bind CpG-B and CpG-A DNA, respectively in plasmacytoid dendritic cells. Activation 
of DHX9 leads to IRF-7 activation and IFNα production, while activation of DHX36 leads to the 
activation of NF-κB and the production of IL-6 and TNFα. siRNA knockdown of DHX9 and DHX36 
inhibited cytokine production in response to the DNA virus HSV-1, while response to the RNA virus 
influenza A was unaffected [103].  
4. Inflammasomes 
Although the sensing of cytoplasmic DNA is linked to the transcriptional induction of type I IFN 
and other pro-inflammatory cytokines, cytosolic DNA has also been shown to trigger the  
caspase-1-dependent maturation of the pro-inflammatory cytokines IL-1β and IL-18 [104,105]. IL-1β, 
a close biological relative of TNFα, is involved in innate cell recruitment, activation of T-lymphocytes 
and induction of fever [106]. IL-18 increases the cytolytic activity and IFNγ production of natural 
killer (NK) cells and influences neutrophil recruitment and activation [106,107]. Growing evidence 
supports the importance of these cytokines in anti-viral defenses [108,109]. Mice lacking either  
one of these cytokines have demonstrated enhanced susceptibility to influenza A virus and HSV-1 
infections [110]. Moreover, pretreating mice with IL-18 protects them from subsequent HSV-1 and 
VV challenge [111,112].  
In contrast to type I IFNs and TNFα, the production of IL-1β is controlled at the level of 
transcription, translation, maturation and secretion [113,114]. Many cell stimuli including TLR-ligands 
activate the transcription of the pro-forms of IL-1β and IL-18. Unlike most other cytokines however, 
these pro-cytokines lack leader sequences and are retained in the cytoplasm rather than loaded into 
secretory vesicles. Maturation (i.e., the cleavage) of pro-IL-1β and pro-IL-18 is catalyzed by the 
cysteine protease caspase-1 (formerly known as IL-1 converting enzyme). In resting cells, caspase-1 
itself is present as an inactive zymogen pro-caspase-1 [115]. A large „inflammasome protein complex‟ 
controls the activity of the inflammatory caspase-1 [115]. Several protein complexes have been shown 
to form inflammasomes upon recognizing specific stimuli. NLRPs 2 to 14, which contain a C-terminal 
LRR-rich domain, a central nucleotide-binding NACHT oligomerization domain, and an N-terminal 
protein–protein interaction pyrin domain (PYD) associate with the PYD containing adaptor molecule 
apoptosis-associated speck-like protein (ASC; also termed pycard or TMS1) [116]. ASC links the 
NLRP‟s via its C-terminal CARD domain to the CARD domain of pro-caspase-1. This close 
association of pro-caspase-1 molecules is then believed to provoke self-cleavage into active caspase-1. 
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Active caspase-1 then cleaves pro-IL-1β and pro-IL18. ASC is critical for caspase-1 activation in 
response to many stimuli [106,107,115,117,118].  
4.1. AIM2 
Cytosolic dsDNA also triggers an ASC dependent activation of caspase-1 resulting in the 
maturation and secretion of IL-1β and IL-18. These findings suggested the existence of an 
inflammsome complex that can be triggered by DNA. Analysis of this response in macrophages 
lacking members of the NLRs revealed normal caspase-1 activation in these cells. Subsequent  
studies from several groups revealed that this response was instead dependent on AIM2 (Absent in 
melanoma-2), an interferon inducible protein that belongs to the same PYHIN family as IFI16 
[105,119–121]. AIM2 recognizes cytosolic dsDNA of self and nonself origin including viral DNA via 
its HIN200 domain in a sequence-independent manner. Contrary to other cytosolic sensors of DNA, 
the recognition of DNA by AIM2 triggers the assembly of an inflammasome complex. Upon DNA 
binding, AIM2 likely undergoes oligomerization and associates with ASC via homotypic pyrin-pyrin 
domain interactions, which in turn recruits pro-caspase 1. Published data has shown that the AIM2 
inflammasome is an integral component of innate sensing of DNA viruses [109]. AIM2 is essential for 
the activation of caspase-1 and proteolytic processing of IL-1β and IL-18 in antigen presenting cells in 
response to infection with MCMV and VV. Furthermore, AIM2-ASC dependent IL-18 secretion and 
NK-cell activation is critical in the early control MCMV infection in vivo [105,109]. In addition to 
viruses, AIM2 has also been shown to recognize Francisella tularensis and as observed for DNA 
viruses appears to be critical in early control of Francisella tularensis infection in vivo. Moreoever, 
AIM2 as well as NLRP3 and IPAF function in a redundant manner in the recognition of Listeria 
monocytogenes [109,122]. 
4.2. NLRP3 
In addition to the AIM2 inflammasome, a number of recent studies have shown that mice deficient 
in NLRP3 are more susceptible to virus infections, particularly RNA viruses [104,123,124]. Loss of 
NLRP3 was found to attenuate the normal IL-1β and IL-18 responses to influenza virus and was 
associated with diminished innate cell recruitment to the lung and increased pathology [123]. Further 
studies revealed that influenza‟s M2 protein, a proton-specific ion channel was needed to trigger the 
NLRP3 inflammasome [124]. Viral RNA has also been shown to trigger NLRP3 activation, although 
this is unlikely to be a direct RNA-NLRP3-interaction. The precise relationship between M2 and RNA 
in NLRP3 activation remains to be clarified. The NLRP3 inflammasome also plays a role in the 
response to adenovirus, a DNA virus [104]. Peritoneal macrophages isolated from NLRP3 or ASC 
deficient mice exposed to adenovirus are unable to secrete mature IL-1β [104]. When challenged  
in vivo, NLRP3 knockout mice had reduced levels of IL-1β, IL-6, CCL4 (MIP-1β) and CXCL10  
(IP-10) in the liver. Recently, a viral NLR homolog was identified in the dsDNA virus, KSHV. The 
KSHV tegument protein ORF63 appears to be an NLR homolog that can inhibit inflammasome 
activation by binding to NLRP1 and NLRP3 [58]. Inflammasome activation suppresses KSHV 
reactivation from latency, suggesting that inflammasome activation and IL-1 mediated signaling 
facilitates KSHV latency. These observations are consistent with a model whereby the KSHV 
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tegument ORF63 protein might bind NLRP3 and/or NLRP1 to block the detrimental effects of 
inflammasome activation.  
Intriguingly, a recent study has revealed a role for IFI16 in the recognition of Kaposi  
sarcoma-associated herpesvirus (KSHV) in endothelial cells. IFI16 is known to recognize viral DNA 
in the cytosol and drive type I Interferon production, as discussed above. In endothelial cells however, 
IFI16 in the nucleus can sense the KSHV DNA and form a complex with the inflammasome adapter 
molecule ASC. These findings suggest that IFI16 can form an inflammasome complex following 
recognition of nuclear DNA during infection with this virus [59]. Figure 2 portrays the cytosolic and 
nuclear receptors known to respond to viral pathogens and their downstream signal pathways. 
Figure 2. Cytosolic and Nuclear Pattern Recognition Receptors (PRRs). A multitude of 
DNA sensors, including IFI16, RNA Polymerase III, DAI, LRRFIP1, and DDX9/36 
recognize DNA and drive type I IFNs and cytokine production. RIG-I and MDA5 
recognize RNA in the cytosol. All of these molecules converge on STING in the case of 
DNA or MAVS in the case of RNA. STING and MAVS then engage either the  
TBK1-IRF3 or the IKKb-NFkB pathways, resulting in the activation of type I IFN 
responses and inflammatory cytokines, respectively. AIM2 (which binds to dsDNA) and 
NLRP3 (which can respond to viral RNA (probably indirectly)) act in the cytosol to 
promote the formation of a multiprotein inflammasome complex that contains the adaptor 
protein ASC, and caspase-1. IFI16 can also detect DNA in the nucleus during KSHV 
infection. Nuclear IFI16 engages ASC which then triggers caspase-1 in the cytosol. 
Activation of caspase-1 results in the proteolytic cleavage of pro-IL-1β and pro-IL-18 to 
IL-1β and IL-18, respectively. The mature cytokines can then be released from the cell. 
 
 
5. Conclusions and Future Perspectives 
Over the past decade our understanding of how the innate immune system detects viruses and 
triggers antiviral responses has increased immensely. Our knowledge of what constitutes a PAMP, 
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once limited to classical TLR activators such as LPS, has recently expanded to include nucleic acids.  
This has led to the discovery of a variety of cytosolic RNA and DNA receptors and their downstream 
signaling pathways. Although our grasp of TLR function has matured significantly over the past 
decade, a number of prominent questions remain regarding cytosolic and nuclear PRR signaling. First, 
many of the cytosolic sensors appear to play redundant roles in viral detection. Such overlapping 
defense strategies may have evolved in order to combat viral evasion mechanisms. Defining the 
function of newly identified PRRs in immune defense to viral infection is an important step in 
understanding their unique or ancillary contributions to pathogenesis.  
Secondly, it remains unclear how some nucleic acid sensors discriminate self from non-self. Just as 
RIG-I recognizes the 5‟ triphosphate moiety found principally on viral RNAs, a mechanism 
presumably exists allowing PRRs such as IFI16 to distinguish between virally derived and host DNA. 
Another question that must be addressed is how viral RNA and DNA is made accessible to PRRs. For 
instance, it is not well understood how nucleic acids are presented to cytosolic sensors in cases such as 
HSV infection where viral DNA is shielded by a capsid in the cytoplasm and replicates within the 
nucleus. As we explore these and other questions it is imperative that we apply our findings in human 
model systems. By encouraging cooperation between basic and clinical communities we can ensure 
that new discoveries are quickly translated into therapeutic strategies.  
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